HuidaGene Therapeutics to Present at Multiple Key Conferences Highlighting Advances in CRISPR-based Therapies

SHANGHAI and MIDDLETOWN (DE), April 01, 2025—HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company at the forefront of next-generation genome medicines, today announced its participation in several prestigious scientific and industry conferences in April 2025. The Company will present new data and insights into its pipeline of CRISPR-based gene-editing and RNA-targeting therapies designed to address severe genetic diseases. These presentations will highlight HuidaGene's innovative work in AI-driven CRISPR tool development, next-generation DNA-editing using hfCas12Max for amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy (DMD), and RNA-targeting approaches with hfCas13Y for MECP2 Duplication Syndrome (MDS).

"At HuidaGene, we are dedicated to advancing precision therapies for some of the most devastating and fatal genetic diseases, including ALS, DMD, and MECP2 duplication syndrome," emphasized Alvin Luk, Ph.D., M.B.A., C.C.R.A., CEO and Co-founder of HuidaGene, regarding the importance of these upcoming presentations. " It's an honor to be invited once again to the CRISPR MEDiCiNE Conference – this time to share clinical-stage progress using our novel CRISPR editing platforms to treat these life-threatening conditions. These disorders leave patients and families with limited options and time. Our continued presence at such global conferences reflects scientific recognition and our deep commitment to delivering durable, one-time gene therapies and expanding access to transformative treatments worldwide."

Upcoming presentations:

• The 2^nd CRISPR MEDiCiNE Conference 2025 (April 8-11, 2025)

o Location: Copenhagen, Denmark

o Website: https://event.fourwaves.com/crisprmed25/pages 

o HuidaGene Therapeutics booth (Bronze Sponsor)

o Presentation: Next-generation CRISPR genome editing to combat fatal genetic diseases and extend lifespan (Alvin Luk)

o Time/Date: 09:06 AM CEST / April 9, 2025

o Panel Discussion: Patient Access to CRISPR Medicine (Alvin Luk)

o Time/Date: 10:30 - 11:30 CEST / April 9, 2025

• The 6^th Annual BIONNOVA Leaders Forum & Expo 2025 (April 9-10, 2025)

o Location: Shanghai, China

o Company roadshow

o Time/Date: 13:30 - 16:30 CST / April 9, 2025

o Presentation: Development and application of novel gene-editing tools (Xin Zhang)

o Time/Date: 09:20 CST / April 10, 2025

• IGC 2025 - 9^th Immunotherapy, Gene Therapy, and Cell Therapy Convention (April 17-18, 2025)

o Location: Beijing, China

o Roundtable Discussion: Path of China’s gene therapy drugs: strategies and challenges for dual registration in China and U.S., clinical registration, clinical batch production, and commercialization

o Time/Date: 12:00 – 12:45 CST / April 17, 2025

o Presentation: Development and application of novel gene-editing tools (Xin Zhang)

o Time/Date: 17:30 CST / April 17, 2025

• 3^rd Annual Shanghai ALS and Motor Neuron Disease Summit (April 19-20, 2025)

o Location: Shanghai, China

o Organizer: Standford University, Huashan Hospital, and Fudan University

o Presentation: CRISPR-Cas13 RNA-editing for MECP2 duplication syndrome: preclinical success to first-in-human study (Prof. Hui Yang)

o Time/Date: 09:25 CST / April 20, 2025

Xin Zhang, M.D., M.Sc., COO and CMO of HuidaGene, highlighted the company's innovations in gene-editing tools: "Through our AI-driven discovery platform, HG-PRECISE^®, we have developed a suite of novel gene-editing tools uniquely suited for hard-to-treat and underserved diseases. These RNA and DNA editors allow us to precisely and safely modulate gene expression, addressing previously intractable conditions to traditional therapies. I'm proud to share HuidaGene's continued leadership in shaping the future of genome medicine for patients who need it most."

Hui Yang, Ph.D., Co-founder and Chief Scientific Advisor of HuidaGene, emphasized the strategic importance of the AI-powered platform: "The HG-PRECISE^® platform we developed at HuidaGene is designed to optimize the next generation of CRISPR gene editors through AI-driven design and in-depth biological insights. This platform has facilitated the creation of global patent-protected tools, including DNA and RNA editors, base editors, and epigenetic modulators, each with broad potential applications across genetic diseases. These advances will set a new standard for the precision and safety of genome editing therapies."

About HuidaGene

HuidaGene utilizes its proprietary AI-driven, CRISPR-based HG-PRECISE^® platform to develop potentially curative genome medicine. The Company is advancing clinical programs, including trials of HG004 (granted ODD & RPDD by FDA and ODD by EMA) 'LIGHT' trial (NCT06088992) and Phase 1/2 international, master-protocol 'STAR' clinical trial (NCT05906953) in RPE65-associated retinal disease, HG202 RNA-editing therapy 'SIGHT-I' first-in-human trial (NCT06031727) and 'BRIGHT' Phase 1 clinical trial (NCT06623279) for nAMD, HG204 RNA-editing therapy (granted ODD & RPDD by FDA and ODD by EMA) 'HERO' trial (NCT06615206) for MECP2 duplication syndrome, and HG302 DNA-editing therapy (granted ODD & RPDD by FDA) first-in-human 'MUSCLE' trial (NCT06594094) for DMD. The preclinical programs include HG303 DNA-editing for ALS and CRISPR RNA-editing therapy for Alzheimer's and Huntington's Disease. With an extensive intellectual property portfolio, HuidaGene is a leader in genome medicines for neurology and ophthalmology. Learn more at huidagene.com or on LinkedIn.